Results 51 to 60 of about 530,197 (354)

Differential Protein Expression Patterns of HOXA13 and HOXB13 Are Associated with Bladder Cancer Progression

Diagnostics, 2023
Bladder cancer is a common urological cancer and has the highest recurrence rate of any cancer. The aim of our study was to profile and characterize the protein expression of homeobox A13 (HOXA13) and homeobox B13 (HOXB13) genes in Malaysian bladder ...
Fee-Wai Chin, Huzlinda Hussin, De-Ming Chau, Teng-Aik Ong, Rosna Yunus, Azad Hassan Abdul Razack, Khatijah Yusoff, Soon-Choy Chan, Abhi Veerakumarasivam   +8 more
doaj   +1 more source

Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer [PDF]

, 2016
The NCI Bladder Cancer Task Force convened a Clinical Trials Planning Meeting (CTPM) Workshop focused on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (NMIBC).
Abrams, Acquaviva, Apolo, Apolo, Atkins, Babjuk, Balbas-Martinez, Berman, Blackburn, Boorjian, Bracci, Brahmer, Brausi, Buchwald, Callahan, Callahan, Champiat, Chen, Cheng, Cheng, Choi, Damrauer, Dash, Delyon, di Martino, Dinney, Drake, Dummer, Emens, Epstein, Freeman, Galluzzi, Garon, Ghasemzadeh, Gofrit, Golden, Goldman, Gospodarowicz, Gray, Gray, Gui, Gulley, Guo, Hammers, Hansel, Harland, Herbst, Herrera-Abreu, Hodi, Hyman, Inman, Iyer, Jarow, Jarow, Kamat, Kandimalla, Kim, Kim, Kitano, Knowles, Kompier, Ku, Lamm, Lamm, Lamm, Lamont, Larkin, Lee, Lerner, Lerner, Liu, Mak, Malmstrom, McConkey, McShane, McShane, Morales, Motzer, Patschan, Plimack, Powles, Quilty, Redman, Redman, Rizvi, Robert, Robert, Sanchez-Carbayo, Sargent, Selby, Sharabi, Sharabi, Sjodahl, Skinner, Snyder, Spranger, Srivastava, Steinberg, Taube, Tomlinson, Topalian, Topalian, Tumeh, Van Allen, Van Allen, Weber, Weiss, Williams, Witjes, Wo, Wolchok, Wolchok, Woo, Yang, Zhang   +114 more
core   +3 more sources

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells [PDF]

, 2015
Sorafenib, a tyrosine kinase inhibitor, has been demonstrated to exert anti-tumor effects. However, the molecular mechanisms underlying its effects on bladder cancer remain unknown.
AMANTINI, Consuelo, BONFILI, LAURA, Cardinali, Claudio, Cascinu, Stefano, ELEUTERI, Anna Maria, FARFARIELLO, Valerio, Morelli, Maria Beatrice, MOZZICAFREDDO, MATTEO, NABISSI, MASSIMO, SANTONI, Giorgio, Santoni, Matteo, Soriani, Alessandra   +11 more
core   +7 more sources

Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma [PDF]

, 2013
Background: Proteomic discovery of cancer biomarkers in body fluids is challenging because of their low abundance in a complex background. Altered gene expression in tumours may not reflect protein levels in body fluids.
A Martin, BM Bolstad, C Parr, C Parr, C Wang, C Yu, D G Ward, D Kaufman, D Tilki, E Cauberg, E Orenes-Piñero, Gordon K Smyth, H Kataoka, H Kawanishi, H Onda, I Waldhauer, J Salo, J Wiśniewski, K Chang, K K Cheng, K Nakamura, L Dyrskjøt, L Mengual, M Babjuk, M Grønborg, M Lindén, M Makridakis, M Muramaki, M P Zeegers, M Sánchez-Carbayo, M Volmer, M Yang, MP Zeegers, N Anderson, N D James, N J Shimwell, N James, N Nagaraj, N Yang, O Nagakawa, P J Johnson, R Bryan, R T Bryan, RA Irizarry, S Ikematsu, S Irmak, S Kageyama, S Ray, S Shariat, T O’Brien, W Wei, Y Chang, Y Chen, Y Lotan, Y Senga   +54 more
core   +6 more sources

Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries

ESMO Open, 2019
The Central European Cooperative Oncology Group (CECOG) and ‘ESMO Open—Cancer Horizons’ roundtable discussion brought together stakeholders from several European Union (EU) countries involved in drug development, drug authorisation and reimbursement or ...
Nils Wilking, Anna Bucsics, Lidlija Kandolf Sekulovic, Gisela Kobelt, Andrea Laslop, Lydia Makaroff, Alexander Roediger, Christoph Zielinski   +7 more
doaj   +1 more source

Knockdown of CDCA8 inhibits the proliferation and enhances the apoptosis of bladder cancer cells [PDF]

PeerJ, 2020
Bladder cancer is a tumour of the urinary system with high mortality, and there is also a great lack of therapeutic targets in the clinic. Cell division cycle associated 8 (CDCA8), an important component of the vertebrate chromosomal passenger complex ...
Xin Gao, Xiaohong Wen, Haowei He, Linlin Zheng, Yibo Yang, Jinlian Yang, Haifang Liu, Xiguo Zhou, Changshun Yang, Yinyi Chen, Mei Chen, Shufang Zhang   +11 more
doaj   +2 more sources

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members

European Urology Open Science, 2023
Background: Grade of non–muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1–3, and WHO2004 categories: papillary ...
Irene J. Beijert, Liang Cheng, Fredrik Liedberg, Karin Plass, Sean R. Williamson, Paolo Gontero, Maria J. Ribal, Marko Babjuk, Peter C. Black, Ashish M. Kamat, Ferran Algaba, David M. Berman, Arndt Hartmann, Alexandra Masson-Lecomte, Morgan Rouprêt, Antonio Lopez-Beltran, Hemamali Samaratunga, Shahrokh F. Shariat, A. Hugh Mostafid, Murali Varma, Steven Shen, Maximilian Burger, Toyonori Tsuzuki, Joan Palou, Eva M. Compérat, Richard J. Sylvester, Theo H. van der Kwast, Bas W.G. van Rhijn, Michelle R. Downes   +28 more
doaj  

Supplementation of Probiotic Butyricicoccus pullicaecorum Mediates Anticancer Effect on Bladder Urothelial Cells by Regulating Butyrate-Responsive Molecular Signatures

Diagnostics, 2021
In bladder cancer, urothelial carcinoma is the most common histologic subtype, accounting for more than 90% of cases. Pathogenic effects due to the dysbiosis of gut microbiota are localized not only in the colon, but also in regulating bladder cancer ...
Yen-Chieh Wang, Wei-Chi Ku, Chih-Yi Liu, Yu-Che Cheng, Chih-Cheng Chien, Kang-Wei Chang, Chi-Jung Huang   +6 more
doaj   +1 more source